These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 30328067)

  • 1. Effect of Changes in Skeletal Muscle Mass on Oncological Outcomes During First-Line Sunitinib Therapy for Metastatic Renal Cell Carcinoma.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Yoshida K; Iizuka J; Tanabe K
    Target Oncol; 2018 Dec; 13(6):745-755. PubMed ID: 30328067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Posttherapeutic skeletal muscle mass recovery predicts favorable prognosis in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy.
    Fukushima H; Kataoka M; Nakanishi Y; Sakamoto K; Takemura K; Suzuki H; Ito M; Tobisu KI; Fujii Y; Koga F
    Urol Oncol; 2018 Apr; 36(4):156.e9-156.e16. PubMed ID: 29051030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postoperative Changes in Skeletal Muscle Mass Predict Survival of Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy.
    Fukushima H; Nakanishi Y; Kataoka M; Tobisu KI; Koga F
    Clin Genitourin Cancer; 2017 Apr; 15(2):e229-e238. PubMed ID: 27601279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 5. Sarcopenia and the Modified Glasgow Prognostic Score are Significant Predictors of Survival Among Patients with Metastatic Renal Cell Carcinoma Who are Receiving First-Line Sunitinib Treatment.
    Ishihara H; Kondo T; Omae K; Takagi T; Iizuka J; Kobayashi H; Tanabe K
    Target Oncol; 2016 Oct; 11(5):605-617. PubMed ID: 27023922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
    Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I
    Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of axitinib and sunitinib as first-line therapies for metastatic renal cell carcinoma: a real-world multicenter analysis.
    Konishi S; Hatakeyama S; Tanaka T; Ikehata Y; Tanaka T; Fujita N; Ishibashi Y; Yamamoto H; Yoneyama T; Hashimoto Y; Yoshikawa K; Kawaguchi T; Masumori N; Kitamura H; Ohyama C
    Med Oncol; 2018 Nov; 36(1):6. PubMed ID: 30474747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of Everolimus Toxicity and Prognostic Value of Skeletal Muscle Index in Patients With Metastatic Renal Cell Carcinoma.
    Auclin E; Bourillon C; De Maio E; By MA; Seddik S; Fournier L; Auvray M; Dautruche A; Vano YA; Thibault C; Joly F; Brunereau L; Gomez-Roca C; Chevreau C; Elaidi R; Oudard S
    Clin Genitourin Cancer; 2017 Jun; 15(3):350-355. PubMed ID: 28216276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of sarcopenia and decreased relative dose intensity during the initial two cycles of first-line sunitinib for metastatic renal cell carcinoma.
    Lee CH; Ku JY; Seo WI; Park YJ; Chung JI; Kim W; Park TY; Ha HK
    J Chemother; 2021 Jul; 33(4):245-255. PubMed ID: 33412998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer.
    Köstek O; Yılmaz E; Hacıoğlu MB; Demircan NC; Gökyer A; Uzunoğlu S; Tunçbilek N; Çiçin İ; Erdoğan B
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):735-742. PubMed ID: 30680522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Negative Effect of Immediate Sunitinib Interruption on Survival in Patients With Metastatic Renal Cell Carcinoma.
    Ishiyama R; Ishihara H; Kondo T; Takagi T; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    In Vivo; 2019; 33(6):2153-2160. PubMed ID: 31662551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Ruiz-Morales JM; Swierkowski M; Wells JC; Fraccon AP; Pasini F; Donskov F; Bjarnason GA; Lee JL; Sim HW; Sliwczynsk A; Ptak-Chmielewska A; Teter Z; Beuselinck B; Wood LA; Yuasa T; Pezaro C; Rini BI; Szczylik C; Choueiri TK; Heng DY
    Eur J Cancer; 2016 Sep; 65():102-8. PubMed ID: 27487293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group.
    Rini BI; Hutson TE; Figlin RA; Lechuga MJ; Valota O; Serfass L; Rosbrook B; Motzer RJ
    Clin Genitourin Cancer; 2018 Aug; 16(4):298-304. PubMed ID: 29853320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma.
    Iacovelli R; Cossu Rocca M; Galli L; Sabbatini R; De Giorgi U; Santini D; Facchini G; Mosca A; Atzori F; Zucali P; Fornarini G; Massari F; Buti S; Ricotta R; Masini C; Toscani I; Biasco E; Guida A; Lolli C; De Lisi D; Rossetti S; Terrone C; Scartozzi M; Miggiano C; Pastorino A; Bersanelli M; Carlo-Stella G; Pinto C; Nobili E; Nolè F; Tortora G; Porta C
    Anticancer Drugs; 2018 Aug; 29(7):705-709. PubMed ID: 29846246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha.
    Dirican A; Kucukzeybek Y; Erten C; Somali I; Demir L; Can A; Payzin KB; Bayoglu IV; Akyol M; Yildiz Y; Koeseoglu M; Alacacioglu A; Tarhan MO
    Asian Pac J Cancer Prev; 2013; 14(3):2101-5. PubMed ID: 23679326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perioperative Skeletal Muscle Fluctuations in High-Acuity Liver Transplantation.
    Chong J; Guorgui J; Coy H; Ito T; Lu M; DiNorcia J; Agopian VG; Farmer DG; Raman SS; Busuttil RW; Kaldas FM
    J Surg Res; 2022 Feb; 270():386-393. PubMed ID: 34739998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of first-line sunitinib in Chinese patients with metastatic renal cell carcinoma.
    Qin SK; Jin J; Guo J; Wang JW; Zhou FJ; Huang YR; Ren XB; Ye DW; Pan S; Sajben P; Wang Q
    Future Oncol; 2018 Aug; 14(18):1835-1845. PubMed ID: 29717651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Skeletal Muscle Loss and Sarcopenia on Outcomes of Locally Advanced Esophageal Cancer during Neoadjuvant Chemoradiation.
    Xiao X; Fang PH; Zhou JF; Li XK; Shang QX; Yang YS; Luan SY; Chen LQ; Yuan Y
    Ann Surg Oncol; 2024 Jun; 31(6):3819-3829. PubMed ID: 38245646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment-related deterioration of renal function is associated with the antitumor efficacy of sunitinib in patients with metastatic renal cell carcinoma.
    Fukuda H; Kondo T; Iida S; Takagi T; Tanabe K
    Urol Oncol; 2016 Aug; 34(8):338.e1-9. PubMed ID: 27085488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No influence of sarcopenia on survival of ovarian cancer patients in a prospective validation study.
    Ubachs J; Koole SN; Lahaye M; Fabris C; Bruijs L; Schagen van Leeuwen J; Schreuder HWR; Hermans RH; de Hingh IH; van der Velden J; Arts HJ; van Ham M; van Dam P; Vuylsteke P; Bastings J; Kruitwagen RFPM; Lambrechts S; Olde Damink SWM; Rensen SS; Van Gorp T; Sonke GS; van Driel WJ
    Gynecol Oncol; 2020 Dec; 159(3):706-711. PubMed ID: 33019981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.